Home > Neurology > MTIS 2020 > Contents > Real-world evidence reveals physicians’ perception of erenumab

Real-world evidence reveals physicians’ perception of erenumab

Presented By
Dr Mirja Koch, Clinical Research Neuroscience, Novartis Pharma GmbH, Germany
Conference
MTIS 2020
Trial
TELESCOPE
  The TELESCOPE study provides real-world evidence data for erenumab –a first-in-class calcitonin gene-related peptide (CGRP) receptor inhibitor– in German headache centres. Based on the assessment of treating physicians, erenumab reduced the burden of migraine and increased quality of life (QoL) in >75% of their patients, with onset after the first injection in a majority of the patients. Erenumab is approved for the preventive treatment of migraine in adults. Real-world data has become increasingly important for providing evidence of treatment effectiveness in clinical practice. TELESCOPE was an online survey, which took place from July until December 2019 in 45 German headache centres, collecting real-world data on erenumab treatment outcome from the physicians’ perception in daily clinical routine [1]. This study captured data on the physician’s perspective on erenumab treatment regarding ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on